TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01711099

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: device for Extracorporeal Shockwave Myocardial Revascularization (ESMR) therapy
Study: NCT02709707

Intervention type: DEVICE
Intervention: Blood glucose monitor
Study: NCT02121639

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD5363
Study: NCT04426357

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-64417184
Description: Participants will receive single oral (as film coated tablet) dose of JNJ-64417184 on Day 1.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: JNJ-64417184
Description: Participants will receive single oral (as film coated tablet) dose of JNJ-64417184 on Day 1.
Study: NCT03855540

Intervention type: DIAGNOSTIC_TEST
Intervention: ECHOcardiography
Description: ECHO parameters~1. LA diameter~2. LVEDD~3. LVEF~4. Diastolic dysfunction~5. Valvular disease

Intervention type: DIAGNOSTIC_TEST
Intervention: ECHOcardiography
Description: ECHO parameters~1. LA diameter~2. LVEDD~3. LVEF~4. Diastolic dysfunction~5. Valvular disease

Intervention type: DIAGNOSTIC_TEST
Intervention: Peripheral blood samples for plasmatic biomarkers
Description: 1. Coagulation~   * D - dimer~  * Fibrinogen~2. Inflammation and fibrosis~   * Hs - CRP~  * AGEs~  * Soluble RAGE~3. Hemodynamics (LA stretch)~   * Apelin~  * NT - proBNP~  * Hs - troponin~4. MiRNA~   * miRNA - 1~  * miRNA - 133~  * miRNA - 29b~  * miRNA - 208a~  * miRNA - 208b~  * miRNA - 499

Intervention type: DIAGNOSTIC_TEST
Intervention: Peripheral blood samples for plasmatic biomarkers
Description: 1. Coagulation~   * D - dimer~  * Fibrinogen~2. Inflammation and fibrosis~   * Hs - CRP~  * AGEs~  * Soluble RAGE~3. Hemodynamics (LA stretch)~   * Apelin~  * NT - proBNP~  * Hs - troponin~4. MiRNA~   * miRNA - 1~  * miRNA - 133~  * miRNA - 29b~  * miRNA - 208a~  * miRNA - 208b~  * miRNA - 499

Intervention type: DIAGNOSTIC_TEST
Intervention: Athens insomnia scale questionnaire
Description: Athens insomnia scale questionnaire

Intervention type: DIAGNOSTIC_TEST
Intervention: Athens insomnia scale questionnaire
Description: Athens insomnia scale questionnaire

Intervention type: DIAGNOSTIC_TEST
Intervention: ECG Holter monitor
Description: Patient receives ECG Holter monitor if included to the control group

Intervention type: DIAGNOSTIC_TEST
Intervention: ECG event recorder
Description: Patient receives ECG event recorder for twice daily (or if symptoms), 90 seconds duration ECG monitoring if included to the control group
Study: NCT01139970

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacological Study
Description: Correlative studies

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Veliparib
Description: Given PO
Study: NCT00599677

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: acupuncture
Description: Subjects are treated five days a week continuously, and for four weeks.They are treated 30min every time.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Itopride
Description: Each pill weighs 50mg, once a pill, three times a day. The pills are taken half an hour before meals, and be taken 4 weeks continuously.
Study: NCT01649102

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Tunneled Cuffed Catheter (Palindroom, Hemoglide Bard)
Description: A tunneled cuffed catheter is inserted, randomization between:~* Palindroom~* Hemoglide Bard

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Tunneled Cuffed Catheter (Palindroom, Hemoglide Bard)
Description: A tunneled cuffed catheter is inserted, randomization between:~* Palindroom~* Hemoglide Bard
Study: NCT03670602

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Episodic Future Thinking
Description: Participants will practice using these cues when making decisions about health choices. Participants will implement EFT while using The Traffic Light Diet, The Traffic Light Activity Program, and a variety of behavioral techniques including stimulus control, self-monitoring, goal setting, problem solving, resetting rewarding mechanisms by reducing need for immediate gratification, finding behavioral substitutes for highly reinforcing food.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Daily Check in
Description: Participants will be asked to access the electronic app at the same rate as the experimental group (e.g. daily). Participants will receive behavioral weight loss treatment including The Traffic Light Diet, The Traffic Light Activity Program, and a variety of behavioral techniques including stimulus control, self-monitoring, goal setting, problem solving, and finding behavioral substitutes for highly reinforcing food.
Study: NCT00623246

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: MET
Description: MET will involve motivational counseling sessions and phone calls, with a focus on building self-efficacy and providing personalized feedback on health and adherence patterns based on CPAP adherence monitoring.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: ED
Description: ED will involve sessions and phone calls that include educational information, problem-solving, and adherence feedback from study staff.
Study: NCT00074438

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rituximab
Description: Intravenous repeating dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rituximab
Description: Intravenous repeating dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rituximab
Description: Intravenous repeating dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: corticosteroids
Description: Intravenous repeating dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: corticosteroids
Description: Intravenous repeating dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: corticosteroids
Description: Intravenous repeating dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: corticosteroids
Description: Intravenous repeating dose

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: corticosteroids
Description: Intravenous repeating dose

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: corticosteroids
Description: Intravenous repeating dose

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Intravenous repeating dose

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Intravenous repeating dose

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Intravenous repeating dose
Study: NCT02239627

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Epidural steroid

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clonidine
Study: NCT01942473

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Automated FiO2 Control
Description: Infants will be ventilated with or without automated FiO2-Control in a randomized sequence.
Study: NCT01753102

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Estradiol
Description: one tablet will be inserted daily for 14 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Estradiol
Description: one tablet will be inserted daily for 14 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Estradiol
Description: one tablet will be inserted daily for 14 days
Study: NCT04483167

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 99mTccAbVCAM1-5 injection
Description: intravenous injection of 99mTccAbVCAM1-5 with dose increase
Study: NCT00979069

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Aerobic group
Description: 12 weeks of aerobic exercise 3 times a week
Study: NCT00240227

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prazosin
Description: FDA approved medication for hypertension

Intervention type: DRUG
Group type: OTHER
Intervention: placebo
Study: NCT04155853

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Interposition Arthroplasty
Description: A typical Wagner incision will be used at the thenar skin one centimeter distal to the radial styloid. The interval between the abductor pollicis longus and the extensor pollicis brevis will be developed, while protecting the dorsal sensory branches of the radial nerve. A longitudinal capsulotomy will be performed and after identifying the carpometacarpal and scaphotrapeziotrapezoid joints, the trapezium will be excised. Then, the empty space will be filled with a roll of fascia lata and fixed with a K-wire. The 1.4 millimeter K-wire will be introduced two centimeters distally to the metacarpal base and into the body of the trapezium. In case of scaphotrapeziotrapezoid joint arthritis, debridement and osteophyte excision of the scaphotrapezoid joint will be performed. In the end of the procedure, the capsule and the skin will be sutured, and a thumb spica will be placed to all patients.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Hematoma and Distraction Arthroplasty
Description: A typical Wagner incision will be used at the thenar skin one centimeter distal to the radial styloid. The interval between the abductor pollicis longus and the extensor pollicis brevis will be developed, while protecting the dorsal sensory branches of the radial nerve. A longitudinal capsulotomy will be performed and after identifying the carpometacarpal and scaphotrapeziotrapezoid joints, the trapezium will be excised. Then, the empty space will be stabilized with a K-wire without interposition of any material. The 1.4 millimeter K-wire will be introduced two centimeters distally to the metacarpal base and into the body of the trapezium. In case of scaphotrapeziotrapezoid joint arthritis, debridement and osteophyte excision of the scaphotrapezoid joint will be performed. In the end of the procedure, the capsule and the skin will be sutured, and a thumb spica will be placed to all patients.
Study: NCT03404609

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MagPro X100 by MagVenture
Description: Participants received 5 consecutive days of accelerated cTBSmod to the right frontal pole. Each cTBSmod session was comprised of 1800 pulses, delivered in a continuous train of 600 bursts. Each burst contained 3 pulses at 30 Hz, repeated at 6 Hz. Ten sessions were applied per day (18,000 pulses/day, hourly) (90,000 total pulses) using a Magventure Magpro X100. Stimulation was delivered at 90% resting motor threshold (depth corrected). Localite Neuronavigation System was used to position the TMS coil over the individualized stimulation target.
Study: NCT03538431

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Buspirone
Description: Buspirone is an atypical anxiolytic medication.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Buspirone
Description: Buspirone is an atypical anxiolytic medication.
Study: NCT04112524

Intervention type: DEVICE
Intervention: App
Description: * Alleye® Test Alleye® Test is a mobile medical software application indicated for the detection and characterization of metamorphopsia. For the mean Alleye score (±standard deviation (SD) deviations of dots from an ideal line are calculated for each eye.~* AMD-A Metamorphopsia Detector® Is based on the Amsler grid. The software uses the concept of a negative image: a distorted image can be straightened by moving the mouse. Degree and dimension of distorted lines or scotoma are transformed into indices.
Study: NCT00287651

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Pulsatile IV Insulin
Description: Intravenous Insulin is provided in a pulsed manner based upon weekly physician orders the amount of insulin provided is dependent on patients level of insulin resistance.
Study: NCT01071785

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: guar gum
Description: guar gum 10g/day for six weeks
Study: NCT03851666

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: 12 weeks daily administration Cereal 1
Description: The subjects will come to a visit every 4 weeks for a total period of 12 weeks. At the first, the second and the third visit the subjects will be supplied with a 5-week supply of product.~Each daily administration will be supplied in a sachet. Subjects will be instructed to mix the contents of the sachet with 200mL of water and drink the solution within 5 minutes after preparation.~The daily dose administrated is 15 grams.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: 12 weeks daily administration Cereal 2
Description: The subjects will come to a visit every 4 weeks for a total period of 12 weeks. At the first, the second and the third visit the subjects will be supplied with a 5-week supply of product.~Each daily administration will be supplied in a sachet. Subjects will be instructed to mix the contents of the sachet with 200mL of water and drink the solution within 5 minutes after preparation.~The daily dose administrated is 15 grams.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: 12 weeks daily administration Placebo
Description: The subjects will come to a visit every 4 weeks for a total period of 12 weeks. At the first, the second and the third visit the subjects will be supplied with a 5-week supply of placebo.~Each daily administration will be supplied in a sachet. Subjects will be instructed to mix the contents of the sachet with 200mL of water and drink the solution within 5 minutes after preparation.
Study: NCT03338920

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sumatriptan nasal powder
Description: nasal powder administered via nosepiece

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: lactose monohydrate powder administered via nosepiece
Study: NCT02732496

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Targeted Cognitive Training (TCT)
Description: The instructors have selected a set of computer exercises designed to specifically target working memory, which is a cognitive construct relevant to ADHD and Tourette Syndrome. The tasks were designed to benefit subjects through principles of learning-dependent plasticity.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Youth Appropriate Online Games
Description: Engaging games not designed to improve cognition.
Study: NCT04466033

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Magneto Microcatheter
Description: All patients will be treated with Magneto Microcatheter
Study: NCT02274233

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SP-420

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SP-420

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SP-420

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SP-420

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SP-420

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SP-420
Study: NCT01287208

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Activity monitor
Description: The activity monitor is an accelerometer that records steps, distance, calories, and sleep

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Activity device
Description: Accelerometer that has all the steps, distance, calories, and sleep data blinded to the study subject
Study: NCT01906138

Intervention type: DEVICE
Group type: OTHER
Intervention: SENSIMED Triggerfish®
Description: All eligible patients will be assigned to 24-hour intraocular pressure recording using Triggerfish
Study: NCT02437526

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Analytic treatment interruption
Study: NCT01399645

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Liraglutide-metformin vs insulin-metformin
Description: Liraglutide (Victoza, Novo Nordisk) at a dose of 0.6 - 1.8 mg subcutaneous per day.~Insulin glargine (Lantus, Sanofi-Aventis) with an initial bedtime starting dose of 10 IU.
Study: NCT00287651

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Effects of Pulsatile IV Insulin on Diabetic Retinopathy
Description: Control Patients are not given pulsatile intravenous insulin therapy during the study.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Effects of Pulsatile IV Insulin on Diabetic Retinopathy
Description: Intravenous Insulin is provided in a pulsed manner based upon weekly physician orders the amount of insulin provided is dependent on patients level of insulin resistance.
Study: NCT00837928

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bendamustine
Description: 40 mg/m2 will be administered IV on days 1,2,and 3 prior to surgery.on each day of SRT.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: samples will be obtained on day 1 or 2 only from patients undergoing surgery on day 3 (i.e. PK samples will not be collected from patients who begin SRT on day 1).

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgical Resection of Brain Metastases
Description: Surgical Resection of Brain Metastases Day 3 (immediately after Bendamustine)

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic body radiation therapy
Description: Starting at least 4 weeks after surgery (Day 1 if no surgery ); 30 Gy in 5 daily fractions(Mon-Fri)
Study: NCT04644536

Intervention type: DEVICE
Intervention: Bone graft substitute
Description: Orthopaedic or Spine bony defects

Intervention type: DEVICE
Intervention: Bone graft substitute
Description: Orthopaedic or Spine bony defects
Study: NCT02909257

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Same Bupivacaine Concentration
Description: patient is exposed to the same concentration than previously successful one

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lower Bupivacaine Concentration
Description: patient is exposed to a lower concentration than previously successful one
Study: NCT04644536

Intervention type: DEVICE
Intervention: Bone graft substitute
Description: Orthopaedic or Spine bony defects

Intervention type: DEVICE
Intervention: Bone graft substitute
Description: Orthopaedic or Spine bony defects

Intervention type: DEVICE
Intervention: Bone graft substitute
Description: Orthopaedic or Spine bony defects
Study: NCT01879878

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Verum, broccoli sprout grain
Description: Patients will be randomly classified into two groups - verum and placebo. The patients in the experimental arm will receive capsules with broccoli sprout grain containing a total of 90mg sulforaphane active substance per day over one year as nutrition supplement whereas patients assigned to the placebo group will receive inactive substance (methylcellulose) with identical capsule and portion distribution.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Patients assigned to the placebo group will receive inactive substance (methylcellulose) with identical capsule and portion distribution as the experimental arm.
Study: NCT02782182

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FOLFIRINOX (oxaliplatin, leucovorin, irinotecan)
Description: FOLFIRINOX administered preoperatively and postoperatively
Study: NCT01281761

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cetuximab/irinotecan/simvastatin
Description: D1 Cetuximab 500mg/m2 IV stepwise shortened infusion duration- \[C1D1 over 120min, C2D1 over 90min,subsequent dose over 60min\] D1 Irinotecan 150-180mg/m2 + Dextrose 5% 500ml IV \[over 90min\] D1-14 Simvastatin 80mg P.O(continuous, daily) every 2weeks
Study: NCT03139279

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Description: Dexmedetomidine 0.3 ug/kg intravenous bolus

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Saline placebo
Description: Intravenous saline/placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propofol
Description: Propofol titrated intravenous boluses

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Propofol
Description: Propofol titrated intravenous boluses
Study: NCT03925246

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Nivolumab (Opdivo) is a potent human monoclonal antibody (mAb) of the IgG4 isotype designed to directly block the interaction between Programmed Cell Death 1 (PD-1) and its ligands, Programmed Death Ligand 1 (PD-L1) and PD-L2.~Nivolumab is administered by a 30 minutes intravenous infusion at dose of 240 mg every 2 (+/- 2 days) weeks for 8 cycles (4 months), followed by a dose of 480 mg administered by a 60 minutes intravenous infusion every 4 weeks (+/-3 days) (beginning at cycle 9) for a total therapy duration of 1 year (maximum 16 cycles of treatment) or until progression, death, unacceptable toxicity.
Study: NCT04246749

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [14C]-CRN00808
Description: Investigational drug

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [14C]-CRN00808
Description: Investigational drug

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CRN00808
Description: Investigational drug
Study: NCT03773562

Intervention type: DRUG
Group type: OTHER
Intervention: Erenumab
Description: Erenumab will be used per label instructions.
Study: NCT05214508

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: interleukin 6
Description: assessment of serum IL-6 by ELISA
Study: NCT00745667

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: laparoscopic surgery
Description: laparoscopic correction perforated peptic ulcer

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Upper laparotomy
Description: upper laparotomy for correction of perforated peptic ulcer
Study: NCT04679987

Intervention type: DIAGNOSTIC_TEST
Intervention: Holter ECG
Description: all patients will be monitored for paroxysmal Af by holder ECG

Intervention type: DIAGNOSTIC_TEST
Intervention: Holter ECG
Description: all patients will be monitored for paroxysmal Af by holder ECG
Study: NCT00567229

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rituximab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lenalidomide

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: microarray analysis

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: flow cytometry

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Study: NCT01522872

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TH-302

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TH-302 and Dexamethasone

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TH-302 Dose Escalation and Dexamethasone in Combination with Bortezomib

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TH-302 Dose Escalation and Dexamethasone in Combination with Pomalidomide
Study: NCT04190173

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prucalopride
Description: 1-2 mg once daily enteral feeding for 5 consecutive days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 1/2-1 tablet once daily enteral feeding for 5 consecutive days